NLRP3 and COVID-19: Moreover, NLRP3 inhibitors have also been tested in a few clinical trials for COVID‐19 such as melatonin (TrialTroveID‐375830), colchicine (TrialTroveID‐381747), and cyclosporine A (TrialTroveID‐383935) and the outcomes of the completed trials are encouraging.10